Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 January 2013

Clinical Trials, Cohort Studies, Pilot Studies

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial. De Meyer S, Dierynck I, Ghys A, et al. Hepatology. 2012 Dec;56(6):2106-15. doi: 10.1002/hep.25962.

http://www.ncbi.nlm.nih.gov/pubmed/22806681

Efficacy and safety of low-dose peginterferon alpha-2a plus ribavirin on chronic hepatitis C. Yan Z, Fan K, Wang X, Mao Q, Deng G, Wang Y. Gastroenterol Res Pract. 2012;2012:302093. doi: 10.1155/2012/302093. Epub 2012 Dec 3.

http://www.ncbi.nlm.nih.gov/pubmed/23258976

Retreatment with Peginterferon α-2a + Ribavirin in Patients Who Failed Previous Peginterferon α-2b + Ribavirin Combination Therapy. Ueda T, Tsuchiya K, Hashimoto S, et al. Dig Dis. 2012;30(6):554-60. doi: 10.1159/000343064. Epub 2012 Dec 13.

http://www.ncbi.nlm.nih.gov/pubmed/23258094

Taste and appetite disorders of chronic hepatitis C patients. Musialik J, Suchecka W, Klimacka-Nawrot E, et al. Eur J Gastroenterol Hepatol. 2012 Dec;24(12):1400-5. doi: 10.1097/MEG.0b013e3283589f63.

http://www.ncbi.nlm.nih.gov/pubmed/22932161

Assessment and Utilization of Rapid Virologic Response in US Veterans With Chronic Hepatitis C: Evaluating Provider Adherence to Practice Guidelines. Hwang EW, Thomas I, Cheung R, Backus LI. J Clin Gastroenterol. 2012 Dec 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23269309

Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Lawitz E, Rodriguez-Torres M, Denning JM, et al. Antimicrob Agents Chemother. 2012 Dec 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23263000

Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. Huang CF, Yu ML, Kao JH, et al. J Clin Virol. 2012 Dec 13. pii: S1386-6532(12)00435-0. doi: 10.1016/j.jcv.2012.11.015. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23246359

No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: The ATRACTION study, a phase II randomised trial. Schuchmann M, Kittner JM, Schlaak JF, et al. Dig Liver Dis. 2012 Dec 12. pii: S1590-8658(12)00426-4. doi: 10.1016/j.dld.2012.11.006. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23245590

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. van der Meer AJ, Veldt BJ, Feld JJ, et al. JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.

http://www.ncbi.nlm.nih.gov/pubmed/23268517

Effects of triple-drug therapy with nitazoxanide, high-dose ribavirin and peginterferon-α-2a in patients with chronic hepatitis C. Basu PP, Rayapudi K, Shah NJ, Krishnaswamy N, Brown RS. Hepatol Res. 2012 Dec 5. doi: 10.1111/hepr.12013. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23228134

Association of γ-glutamyltransferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Everhart JE, Wright EC. Hepatology. 2012 Dec 19. doi: 10.1002/hep.26203. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23258530

Basic and Applied Science, Pre-Clinical Studies

MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells. Thibault PA, Huys A, Dhillon P, Wilson JA. Virology. 2012 Dec 12. pii: S0042-6822(12)00567-3. doi: 10.1016/j.virol.2012.11.007. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23245472

Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinaemia are associated with circulating levels of IFN-gamma and TNF-alpha. Antonelli A, Fallahi P, Ferrari SM, et al. Clin Exp Rheumatol. 2012 Nov-Dec;30(6):864-70. Epub 2012 Dec 17.

http://www.ncbi.nlm.nih.gov/pubmed/22766105

Characterization of the inhibition of hepatitis C virus entry by in vitro generated and patient derived oxidized low density lipoprotein. Westhaus S, Bankwitz D, Ernst S, et al. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26190. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23212706

Impaired TLR3-mediated immune responses from macrophages of patients chronically infected with Hepatitis C virus. Qian F, Bolen CR, Jing C, et al. Clin Vaccine Immunol. 2012 Dec 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23220997

Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians. Zheng MH, Xiao DD, Shi KQ, et al. Gene. 2012 Dec 20. pii: S0378-1119(12)01597-1. doi: 10.1016/j.gene.2012.12.067. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23266640

Low Oxygen Tension Enhances Hepatitis C Virus Replication. Vassilaki N, Kalliampakou KI, Kotta-Loizou I, et al. J Virol. 2012 Dec 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23269812

HIV/HCV Coinfection

Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir.

Hulskotte EG, Feng HP, Xuan F, et al. Clin Infect Dis. 2012 Dec 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23155151

IL28B Polymorphism, Blood Interferon-alpha Concentration, and Disease Stage of HCV Mono-infected and HCV-HIV Co-infected Patients. Burlone ME, Cerutti A, Minisini R, et al. Curr HIV Res. 2012 Dec 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23237012

Rapid Progression to Decompensated Cirrhosis, Liver Transplantation, and Death in HIV-infected Men after Primary HCV Infection. Fierer DS, Dieterich DT, Fiel MI, et al. Clin Infect Dis. 2012 Dec 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23264364

Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of HBV or Hepatitis C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Kovari H, Sabin CA, Ledergerber B, et al. Clin Infect Dis. 2012 Dec 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23090925

Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. Borghi V, Bisi L, Manzini L, Cossarizza A, Mussini C. Infection. 2012 Dec 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23225268

Association Of Hepatitis C With Markers Of Hemostasis In HIV-Infected and Uninfected Women in the Women's Interagency HIV Study (WIHS). Kiefer EM, Shi Q, Hoover D, et al. J Acquir Immune Defic Syndr. 2012 Dec 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23221984

A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. Neukam K, Almeida C, Caruz A, et al. J Antimicrob Chemother. 2012 Dec 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23243129

Complementary and Alternative Medicine

Vitamin A deficiency is associated with HCV chronic infection and with unresponsiveness to interferon based antiviral therapy. Bitetto D, Bortolotti N, Falleti E, et al. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26186. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23213086

Effects of coffee consumption in chronic hepatitis C: A randomized controlled trial.

Cardin R, Piciocchi M, Martines D, Scribano L, Petracco M, Farinati F. Dig Liver Dis. 2012 Dec 10. pii: S1590-8658(12)00424-0. doi: 10.1016/j.dld.2012.10.021. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23238034

Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction. Chen WC, Wang SY, Chiu CC, et al. Antimicrob Agents Chemother. 2012 Dec 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23254429

Epidemiology, Diagnostics, and Miscellaneous Works

Prevalence and Characteristics of Herpes Simplex Virus Type-2 Coinfection in Veterans With Hepatitis C. Burton MJ, Penman A, Adams-McAlpine G, Overman TL, Hook EW 3rd. Am J Med Sci. 2012 Dec;344(6):436-440.

http://www.ncbi.nlm.nih.gov/pubmed/22395713

Hepatitis C Therapy: Highlights From the 2012 Annual Meeting of the European Association for the Study of the Liver. Barreiro P, Vispo E, Poveda E, Fernández-Montero JV, Soriano V. Clin Infect Dis. 2012 Dec 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23090932

Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection. Kant J, Möller B, Heyne R, et al. Eur J Gastroenterol Hepatol. 2012 Dec 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23211286

Pathogenesis of hepatitis C during pregnancy and childhood. Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Viruses. 2012 Dec 6;4(12):3531-50. doi: 10.3390/v4123531.

http://www.ncbi.nlm.nih.gov/pubmed/23223189

The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective. Menzin J, White LA, Nichols C, Deniz B. BMC Health Serv Res. 2012 Dec 15;12:459. doi: 10.1186/1472-6963-12-459.

http://www.ncbi.nlm.nih.gov/pubmed/23241078

Comparison of three different HCV genotyping methods: Core, NS5B sequence analysis and line probe assay. Cai Q, Zhao Z, Liu Y, Shao X, Gao Z. Int J Mol Med. 2012 Dec 12. doi: 10.3892/ijmm.2012.1209. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23241873

Second Generation COBAS(R) AmpliPrep/COBAS(R) TaqMan(R) HCV Quantitative Test for Viral Load Monitoring: A Novel Dual-Probe Assay Design. Zitzer H, Heilek G, Truchon K, et al. J Clin Microbiol. 2012 Dec 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23241371

Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection. Page K, Osburn W, Evans J, et al. Clin Infect Dis. 2012 Dec 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23090930

Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States. Scott JD, Unruh KT, Catlin MC, et al. J Telemed Telecare. 2012 Dec 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23209269

Liver Cancer

Analysis of Extrahepatic Multiple Primary Malignancies in Patients with Hepatocellular Carcinoma according to Viral Infection Status. Kai K, Miyoshi A, Kitahara K,et al. Int J Hepatol. 2012;2012:495950. doi: 10.1155/2012/495950. Epub 2012 Dec 1.

http://www.ncbi.nlm.nih.gov/pubmed/23251807

Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Diaz-Sanchez A, Matilla A, Nuñez O, et al. Scand J Gastroenterol. 2012 Dec 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23249262

Projected future increase in aging hepatitis C virus-infected liver transplant candidates: A potential effect of hepatocellular carcinoma. Biggins SW, Bambha KM, Terrault NA, et al. Liver Transpl. 2012 Dec;18(12):1471-8. doi: 10.1002/lt.23551.

http://www.ncbi.nlm.nih.gov/pubmed/23008049

Risk of Hepatocellular Carcinoma Development in Cases of Hepatitis C Treated by Long-Term, Low-Dose PEG-IFNα-2a. Hagiwara S, Sakurai T, Takita M, et al. Dig Dis. 2012;30(6):561-7. doi: 10.1159/000343065. Epub 2012 Dec 13.

http://www.ncbi.nlm.nih.gov/pubmed/23258095

Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection. Nishida N, Arizumi T, Hayaishi S, et al. Dig Dis. 2012;30(6):547-53. doi: 10.1159/000343057. Epub 2012 Dec 13.

http://www.ncbi.nlm.nih.gov/pubmed/23258093

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Akuta N, Suzuki F, Seko Y, et al. Hepatology. 2012 Dec;56(6):2134-41. doi: 10.1002/hep.25949.

http://www.ncbi.nlm.nih.gov/pubmed/22806754